Skip to main content

Table 1 Patient demographics and characteristics

From: Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study

Patient No.

ECOG PS

Histological subtype

Stage

Primary site

Metastatic site

Previous lines of chemotherapy

Response

PFS (Months)

1

1

UPS

IV

Head

Lung and bone

1

PR

5

2

1

UPS

IV

Extremities

Lung and lymph nodes

1

PR

3.5

3

0

UPS

IV

Extremities

Lung and bone

2

SD

3

4

0

UPS

IV

Neck

Bone

2

SD

2.5

5

0

UPS

IV

Extremities

Lung

2

PD

2

6

0

UPS

IV

Extremities

Bone

2

PD

1.8

7

1

UPS

IV

Extremities

Lung

1

PD

1

8

1

Angiosarcoma

IV

Head

Liver

2

CR

15

9

0

Angiosarcoma

IV

Trunk

Bone

2

PR

7.8

10

1

Angiosarcoma

IV

Extremities

Lung

2

PR

4

11

0

Angiosarcoma

IV

Extremities

Lung

2

SD

4.5

12

0

Angiosarcoma

IV

Trunk

Lung

2

PD

2

13

1

Epithelioid sarcoma

IV

Extremities

Lung

2

PR

2.8

14

1

Epithelioid sarcoma

IV

Trunk

Lung and lymph nodes

2

SD

3

15

1

Epithelioid sarcoma

IV

Trunk

Lung

2

SD

2.8

16

0

Epithelioid sarcoma

IV

Extremities

Lung

1

PD

1.8

17

1

Epithelioid sarcoma

IV

Extremities

Lung and bone

2

PD

1.3

18

1

Fibrosarcoma

IV

Trunk

Lung

2

PR

4.3

19

1

Fibrosarcoma

IV

Extremities

Lung

2

SD

2.5

20

0

Fibrosarcoma

IV

Extremities

Lung

1

PD

1.5

21

0

Fibrosarcoma

IV

Extremities

Liver

3

PD

1.3

22

0

Synovial sarcoma

IV

Neck

Lung

2

PD

1.8

23

0

Synovial sarcoma

IV

Extremities

Lung

2

PD

1.5

24

1

Synovial sarcoma

IV

Trunk

Lung

3

PD

1.5

25

0

Leiomyosarcoma

IV

Extremities

Lung

2

SD

2.8

26

1

Leiomyosarcoma

IV

Trunk

Liver

1

PD

1.3

27

0

Pleomorphic liposarcoma

IV

Extremities

Lung

2

PD

1.8

28

1

Rhabdomyosarcoma

IV

Head

Lung

1

PD

1.5

  1. The clinical and pathologic stages are expressed according to the American Joint Committee on Cancer (8th Edition) TNM staging. Tumor responses were evaluated according to the Response Evaluation Criteria in Solid Tumors (version 1.1), and were categorized as CR Complete response, PR Partial response, SD Stable disease, or PD Progressive disease. PFS Progression-free survival was calculated from the date of the first nab-paclitaxel plus PD-1 inhibitor treatment until the date of documented progression
  2. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, UPS Undifferentiated pleomorphic sarcoma